Innate Pharma
(NASDAQ) IPHA
Innate Pharma Financials at a Glance
Market Cap
$168.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
€15.41M
Net Income (TTM)
-€98.44M
EPS (TTM)
-$0.61
P/E Ratio
-2.92
Dividend
$0.00
Beta (Volatility)
0.69 (Low)
Dividend
$0.00
Beta (Volatility)
0.69 (Low)
Price
$1.77
Volume
11,787
Open
$1.79
Price
$1.77
Volume
11,787
Open
$1.79
Previous Close
$1.79
Daily Range
$1.76 - $1.81
52-Week Range
$1.17 - $2.63
Estimated Earnings Date
Sep 17, 2026
Dividend
$0.00
Beta (Volatility)
0.69 (Low)
Price
$1.77
Volume
11,787
Open
$1.79
Previous Close
$1.79
Daily Range
$1.76 - $1.81
52-Week Range
$1.17 - $2.63
Estimated Earnings Date
Sep 17, 2026
IPHA News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Innate Pharma
Industry
Biotechnology
Sector
Health CareEmployees
163
CEO
Jonathan Dickinson, MBA
Website
www.innate-pharma.comHeadquarters
Marseille, PA 13009, FR
IPHA Financials
Key Financial Metrics (TTM)
Gross Margin
100.00%
Operating Margin
-2058.02%
Net Income Margin
-1764.51%
Return on Equity
593.93%
Return on Capital
-6150.49%
Return on Assets
-78.41%
Earnings Yield
-34.25%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$168.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
93.90M
Volume
11.79K
Avg. Volume
70.69K
Financials (TTM)
Gross Profit
€15.41M
Operating Income
-€105.00M
EBITDA
-€102.68M
Operating Cash Flow
-€64.33M
Capital Expenditure
-€539.40K
Free Cash Flow
-€64.87M
Cash & ST Invst.
€34.30M
Total Debt
€22.56M
Innate Pharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
-€2.07M
-112.5%
Gross Profit
€18.45M
+690.1%
Gross Margin
-8.90%
N/A
Market Cap
$168.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$929.95K
N/A
Employees
181
N/A
Net Income
-€27.63M
-197.4%
EBITDA
-€30.71M
-195.4%
Quarterly Fundamentals
Total Cash
€34.30M
-62.9%
Total Debt
€22.56M
-43.4%
Accounts Receivable
€7.61M
-83.6%
Inventory
€0.00
N/A
Long Term Debt
€13.77M
-55.5%
Short Term Debt
€8.80M
-1.5%
Return on Assets
-78.41%
N/A
Return on Invested Capital
-2.20%
N/A
Free Cash Flow
-€23.48M
-11.1%
Operating Cash Flow
-€23.40M
-10.9%